BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38291366)

  • 1. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
    Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
    BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of m
    Wu X; Wang S; Wu X; Chen Q; Cheng J; Qi Z
    J Cancer; 2024; 15(7):2045-2065. PubMed ID: 38434979
    [No Abstract]   [Full Text] [Related]  

  • 3. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
    Wu WL; Wang WY; Yao WQ; Li GD
    Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 6. AKR1B10 inhibits the proliferation and metastasis of hepatocellular carcinoma cells by regulating the PI3K/AKT pathway.
    Tian K; Deng Y; Li Z; Zhou H; Yao H
    Oncol Lett; 2024 Jan; 27(1):18. PubMed ID: 38034486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
    Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.
    Liu Y; Ma J; Wang X; Liu P; Cai C; Han Y; Zeng S; Feng Z; Shen H
    Comput Biol Med; 2023 May; 158():106862. PubMed ID: 37044053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancer.
    Chen C; Shang A; Gao Y; Huang J; Liu G; Cho WC; Li D
    Front Mol Biosci; 2022; 9():968458. PubMed ID: 36203873
    [No Abstract]   [Full Text] [Related]  

  • 13. Comprehensive analysis of the tumor-promoting effect and immune infiltration correlation MAZ from pan-cancer to hepatocellular carcinoma.
    Wang M; Yang X; Meng Y; Jin Z; Cao J; Xiong L; Xiong Z
    Int Immunopharmacol; 2023 Feb; 115():109660. PubMed ID: 36623412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma.
    Li W; Liu J
    Front Immunol; 2022; 13():845585. PubMed ID: 35757728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
    Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
    BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1.
    Lee S; Kang E; Lee U; Cho S
    BMC Cancer; 2023 Jul; 23(1):703. PubMed ID: 37495969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EXOSC10 is a novel hepatocellular carcinoma prognostic biomarker: a comprehensive bioinformatics analysis and experiment verification.
    Meng ZY; Fan YC; Zhang CS; Zhang LL; Wu T; Nong MY; Wang T; Chen C; Jiang LH
    PeerJ; 2023; 11():e15860. PubMed ID: 37701829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway.
    Tian T; Nan KJ; Guo H; Wang WJ; Ruan ZP; Wang SH; Liang X; Lu CX
    Oncol Rep; 2010 Jun; 23(6):1593-600. PubMed ID: 20428814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
    Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
    Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.